Identifying a New Target for Kidney Cancer Immunotherapy
Author Information
Author(s): Broen Kelly, Levenga Henriette, Vos Johanna, van Bergen Kees, Fredrix Hanny, Greupink-Draaisma Annelies, Kester Michel, Falkenburg J. H. Frederik, de Mulder Pieter, de Witte Theo, Griffioen Marieke, Dolstra Harry
Primary Institution: Radboud University Nijmegen Medical Centre
Hypothesis
Can minor histocompatibility antigens (MiHA) be effectively targeted in renal cell carcinoma (RCC) treatment using allogeneic stem cell transplantation?
Conclusion
The study identifies a novel MiHA, ZAPHIR, which can be targeted by T cells in RCC patients after allogeneic stem cell transplantation.
Supporting Evidence
- ZAPHIR-specific CD8+ T cells were detected in the blood of RCC patients after transplantation.
- Emergence of SMCY-specific CTLs was observed in one patient without signs of graft-versus-host disease.
- Whole genome association scanning linked the novel MiHA to a polymorphism in the ZNF419 gene.
Takeaway
Researchers found a new target in kidney cancer that the immune system can recognize and attack, which could help treat patients better.
Methodology
The study evaluated T cell responses in two RCC patients treated with reduced-intensity conditioning stem cell transplantation followed by donor lymphocyte infusion.
Limitations
The study involved only two patients, limiting the generalizability of the findings.
Participant Demographics
Two male patients with metastatic renal cell carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website